Halozyme (NASDAQ:HALO) stock rose on Wednesday after the company raised 2025 guidance, prompting a rating upgrade by Morgan Stanley. The company raised 2025 revenue in the range between $1,275M and $1 ...

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

Halozyme Therapeutics Inc (HALO) reports a 41% revenue increase, raises 2025 guidance, and advances share repurchase program ...

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the San Diego-based company said it had ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

Highlights,A key director reduced their stake in Halozyme Therapeutics during the past year,The transaction was executed ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...